Clinical trial
Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
NCT00199901 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00199901 |
|---|---|
| Title | Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma |
| Official title | Randomized, Double-blind Phase II Trial of NY-ESO-1 ISCOMATRIX® Vaccine and ISCOMATRIX® Adjuvant Alone in Patients With Resected Stage Ilc, Illb, lIIc, or IV Malignant Melanoma |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | Institute of Cancer Research, United Kingdom |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | NY-ESO-1 ISCOMATRIX®, ISCOMATRIX® adjuvant |
| Enrollment | 111 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2011 |
| First posted | Sep 20, 2005 |
| Last update posted | Oct 12, 2022 |
| Countries | Australia, New Zealand, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: